Search for: "Warner Chilcott, Inc." Results 21 - 40 of 45
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jul 2011, 10:48 am by admin
., Inc.; ACTONEL (risedronate sodium) tablets, ATELVIA (risedronate sodium) delayed release tablets, and ACTONEL WITH CALCIUM (Copackaged) (risedronate sodium with calcium carbonate) tablets, Warner Chilcott, LLC; BONIVA (ibandronate sodium) tablets and injection, Roche Therapeutics, Inc.; RECLAST (zoledronic acid) injection, Novartis Pharmaceuticals Corp.; and the generic equivalents for these products, if any. [read post]
24 Dec 2008, 3:00 pm
Apotex, Inc (Managing Intellectual Property)     [read post]
9 Nov 2021, 2:54 pm by greggshapiro.admin
Prior authorization requirements are a common hurdle to increased drug sales and, as the earlier cases against Warner-Chilcott and Insys show, pharmaceutical companies have an incentive to overcome those requirements, sometimes by fraud. [read post]
8 May 2009, 8:00 am
(Property intangible) US: Supreme Court rules 9-0 that CAFC has jurisdiction to review case remanded by district court to state court: Carlsbad Technology Inc v HIF Bio, Inc et al (Managing Intellectual Property) (Patently-O) US: Anticipation by a laundry list of prophetic DNA sequences: In re Gleave (Holman's Biotech IP Blog) US: Reverse payment settlements and biotechnology (Holman's Biotech IP Blog) US: Biogen seeks review and correction of patent term adjustment… [read post]
8 Sep 2011, 11:04 am by Tom Lamb
According to the FDA's Announcement for this September 2011 meeting, these two advisory committees will consider the benefits and risks of long-term use of osteoporosis medications in the bisphosphonate class of drugs, which were identified by the FDA as: FOSAMAX (alendronate sodium) tablets and solution and FOSAMAX PLUS D (alendronate sodium/cholecalciferol) tablets, Merck & Co., Inc.; ACTONEL (risedronate sodium) tablets, ATELVIA (risedronate sodium) delayed release… [read post]
28 Feb 2022, 10:46 am by Seeger Weiss
With concentration in the areas of health care and tax fraud, Stephen has represented relators in cases against CareCore National, Warner Chilcott and Life Spine, Inc., and led the first settlement ever reached under the 2010 tax whistleblower amendments to New York’s False Claims Act. [read post]
9 Jul 2020, 10:56 am by Seeger Weiss LLP
Warner Chilcott plc, et al., in which $125 million was recovered in connection with a sprawling healthcare scheme. [read post]
19 Nov 2020, 8:08 pm by Seeger Weiss LLP
Warner Chilcott plc, et al., in which $125 million was recovered in connection with a sprawling healthcare scheme. [read post]
9 Jul 2020, 10:56 am by Seeger Weiss LLP
Warner Chilcott plc, et al., in which $125 million was recovered in connection with a sprawling healthcare scheme. [read post]
15 Jun 2011, 4:56 am by Marie Louise
(Patent Docs) Gemzar (Gemcitabine) – ALJ Rogers rules on motion to quash in Certain Gemcitabine (337-TA-766) (ITC Law Blog) Oestrin 24 Fe (Norethindrone acetate, Ethinyl estradiol) – US: Patent infringement complaint filed in response to Para IV certification: Warner Chilcott Co. v. [read post]
18 Jan 2023, 1:21 pm by Seeger Weiss
With concentration in the areas of health care and tax fraud, Stephen has represented relators in cases against CareCore National, Warner Chilcott and Life Spine, Inc., and led the first settlement ever reached under the 2010 tax whistleblower amendments to New York’s False Claims Act. [read post]
7 Sep 2011, 4:22 am by Marie Louise
  Highlights this week included: US: CAFC: Immunisation methods are patent eligible: Classen Immunotherapies, Inc v Biogen IDEC et al (Inventive Step) (Orange Book Blog) (Patently-O) (Patent Docs) (Patent Docs) (IPBiz) (Patent Law Practice Center) (Patent Baristas) US: FTC issues long-awaited final report on authorized generics; report examines both the short-term effects and long-term impact on competition and drug prices (FDA Law Blog) (Orange Book Blog)   Please join the… [read post]
22 Dec 2010, 3:01 am by Kelly
John’s patent research suit: St John’s University v Sanford M Bolton et al (Patent Docs) US: Affymetrix granted summary judgment for noninfingement of Illumina gene sequencing patents (Patent Docs)   Products Actonel (Risedronate sodium) – US: Patent infringement complaint filed following a Paragraph IV certification: Warner Chilcott Co. [read post]
25 Jun 2010, 1:28 pm by Tom Lamb
We start with a June 24, 2010 Wall Street Journal article, "WellPoint's Data Led It To Limit Use Of Drug Boniva Article", from we learn that the largest U.S. managed care business in terms of membership, WellPoint Inc., has found through internal research that the osteoporosis drug Boniva, which is marketed by Roche Holding AG's Genentech and GlaxoSmithKline PLC, is linked to higher fracture rates than two other bisphosphonates, Actonel, marketed by Sanofi-Aventis SA and… [read post]
8 Feb 2011, 10:51 pm by Marie Louise
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New Jersey: Court precludes jury… [read post]
15 Apr 2010, 4:27 am
(Spicy IP) Argentina: Argentina’s scientific data laws and TRIPs compliance (IP tango) Chile: Secretary General of International Seed Federation visits Chile, pressures nation to sign UPOV 91 (IP tango) EU: AHP Manufacturing BV v Bureau voor de Industriële Eigendom analysis now in print (The SPC Blog) Hungary: Metropolitan Appeal Court: Preliminary injunction refused concerning combination patent (EPLAW) Hungary: Metropolitan Appeal Court of Budapest upholds decision of Metropolitan… [read post]
1 Apr 2010, 3:04 am
MDCO launches another lawsuit against the PTO over Angiomax PTE (FDA Law Blog) Arzerra (Ofatumumab) – US: Biogen files patent infringement suit in S D California against Glaxosmithkline based on manufacture and sale of Arzerra (Patent Docs) Arzerra (Ofatumumab) – US: Genetech files counterclaims in declaratory judgment suit brought by GlaxoSmithKline (Patent Docs) Astelin (Azelastine) – US: District Court New Jersey: Patent infringement complaint following Para IV challenge: Meda… [read post]